Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

184 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Antiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirus.
Kanerva A, Nokisalmi P, Diaconu I, Koski A, Cerullo V, Liikanen I, Tähtinen S, Oksanen M, Heiskanen R, Pesonen S, Joensuu T, Alanko T, Partanen K, Laasonen L, Kairemo K, Pesonen S, Kangasniemi L, Hemminki A. Kanerva A, et al. Among authors: kairemo k. Clin Cancer Res. 2013 May 15;19(10):2734-44. doi: 10.1158/1078-0432.CCR-12-2546. Epub 2013 Mar 14. Clin Cancer Res. 2013. PMID: 23493351 Clinical Trial.
[(18)F]-fluorodeoxyglucose positron emission tomography and computed tomography in response evaluation of oncolytic adenovirus treatments of patients with advanced cancer.
Koski A, Ahtinen H, Liljenback H, Roivainen A, Koskela A, Oksanen M, Partanen K, Laasonen L, Kairemo K, Joensuu T, Hemminki A. Koski A, et al. Among authors: kairemo k. Hum Gene Ther. 2013 Dec;24(12):1029-41. doi: 10.1089/hum.2013.123. Epub 2013 Nov 7. Hum Gene Ther. 2013. PMID: 24099555
Adjuvant radiotherapy for lymph-node positive prostate cancer.
von Eyben FE, Kairemo K, Kiljunen T, Joensuu T. von Eyben FE, et al. Among authors: kairemo k. BJU Int. 2015 Mar;115(3):353-5. doi: 10.1111/bju.12659. Epub 2014 May 22. BJU Int. 2015. PMID: 24854603 No abstract available.
Immunological data from cancer patients treated with Ad5/3-E2F-Δ24-GMCSF suggests utility for tumor immunotherapy.
Hemminki O, Parviainen S, Juhila J, Turkki R, Linder N, Lundin J, Kankainen M, Ristimäki A, Koski A, Liikanen I, Oksanen M, Nettelbeck DM, Kairemo K, Partanen K, Joensuu T, Kanerva A, Hemminki A. Hemminki O, et al. Among authors: kairemo k. Oncotarget. 2015 Feb 28;6(6):4467-81. doi: 10.18632/oncotarget.2901. Oncotarget. 2015. PMID: 25714011 Free PMC article. Clinical Trial.
184 results